** Shares of Celltrion 068270.KS , South Korean biopharma
company, fall as much as 8.1%
** The drop followed Singapore's Temasek Holdings launching two
block sales in Celltrion and its affiliate Celltrion Healthcare
091990.KQ to raise up to 468 billion won ($379 million) and
162 billion won, respectively, according to IFR on Wednesday
** Celltrion said on March 23 that it has completed the first
step of developing an antiviral treatment to fight the
coronavirus, and that it hoped to begin human clinical trials in
the third quarter of this year urn:newsml:reuters.com:*:nFWN2BG03D
** Celltrion shares had risen 30% between March 23 and Wednesday
** The benchmark KOSPI .KS11 fell 1% as of 0011 GMT
(Reporting by Joyce Lee; Editing by Tom Hogue)
((jungyoon.lee@tr.com; +82 2 6936 1467;))